Oxcarbazepine (All indications)

Low birth weight (< 2500g)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10097
R36765		 Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.40 [0.76;2.58] C
excluded (control group) 		12/143   179/2,916 191 143
ref
S9087
R31111		 Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Weight at birth <2500 g during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.62 [0.90;2.93] C 12/143   91,455/1,710,441 91,467 143
ref
S9093
R31151		 Kilic (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.01 [0.57;1.79] C
excluded (control group) 		17/307   48/876 65 307
ref
S9094
R31154		 Kilic (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes 1.50 [0.90;2.40]
excluded (control group) 		17/310   23,503/673,844 23,520 310
ref
S9095
R31157		 Kilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 Low birth weight (< 2500 g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: No Controls: epilepsy indication 1.18 [0.71;1.96] C 17/307   249/5,275 266 307
ref
S9036
R30810		 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No 1.04 [0.41;2.65] C
excluded (control group) 		19/527   6/173 25 527
ref
S9037
R30822		 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, disease free excluded Adjustment: Yes 1.14 [0.72;1.81]
excluded (control group) 		19/527   21,546/719,509 21,565 527
ref
S9038
R30834		 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 Low birth weight (< 2500g) during pregnancy (anytime or not specified) population based cohort retrospective unexposed, sick Adjustment: Yes 1.12 [0.71;1.78] 19/527   65/1,793 84 527
ref
Total 3 studies 1.25 [0.93;1.68] 91,817 977
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020Coste, 2020 1 1.62[0.90; 2.93]91,46714325%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Kilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014Kilic, 2014 2 1.18[0.71; 1.96]26630734%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Artama (Oxcarbazepine) (Controls unexposed, sick), 2013Artama, 2013 3 1.12[0.71; 1.78]8452741%ROB confusion: moderateROB selection: lowROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: moderate Total (3 studies) I2 = 0% 1.25[0.93; 1.68]91,8179770.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, NOS; 2: Oxcarbazepine) (Controls unexposed, sick) (Mixed indications; 3: Oxcarbazepine) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.25[0.93; 1.68]91,8179770%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Kilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.62[0.90; 2.93]91,467143 -NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 1.15[0.82; 1.61]3508340%NAKilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 Tags Adjustment   - No  - No 1.35[0.92; 1.98]91,7334500%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Kilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 2   - Yes  - Yes 1.12[0.71; 1.77]84527 -NAArtama (Oxcarbazepine) (Controls unexposed, sick), 2013 1 Controls   - epilepsy indication  - epilepsy indication 1.18[0.71; 1.96]266307 -NAKilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 1 All studiesAll studies 1.25[0.93; 1.68]91,8179770%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Kilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 30.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 9036, 9037, 9093, 9094, 10097

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.37[1.02; 1.83]136,5529800%NACoste (Oxcarbazepine) (Controls unexposed, NOS), 2020 Kilic (Oxcarbazepine) (Controls unexposed NOS) (Mixed indications), 2014 Artama (Oxcarbazepine) (Controls unexposed, disease free), 2013 3 unexposed, sick controlsunexposed, sick controls 1.15[0.82; 1.61]3508340%NAKilic (Oxcarbazepine) (Controls unexposed, sick) (Mixed indications), 2014 Artama (Oxcarbazepine) (Controls unexposed, sick), 2013 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.15[0.79; 1.69]2819770%NACoste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 Kilic (Oxcarbazepine) (Controls exposed to Lamotrigine, sick) (Mixed indications), 2014 Artama (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2013 30.510.01.0